Refractory
25
9
12
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
4.0%
1 terminated out of 25 trials
50.0%
-36.5% vs benchmark
4%
1 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (25)
Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas
Neoantigen Peptide Vaccine Plus Pembrolizumab in Renal Cell Carcinoma
Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors
xDRIVE for Florida-based Cancer Patients
Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL
Micropulse Laser in Treatment of Initial and Refractory Cases of Center-Involved Diabetic Macular Edema
Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE
The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia
ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells
Long-term Evaluation of Percutaneous Endoscopic Caecostomy in Refractory Constipation
Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia
CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma
A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia
GTP Regimen in the Treatment of Refractory/Recurrent HLH
NK Cell Therapy Recurrent/Refractory Elderly AML